Printer Friendly

GRACE AND DU PONT CROSS-LICENSE KEY GENETIC ENGINEERING TECHNOLOGIES

 GRACE AND DU PONT CROSS-LICENSE
 KEY GENETIC ENGINEERING TECHNOLOGIES
 BOCA RATON, Fla., April 21 /PRNewswire/ -- W. R. Grace & Co. (NYSE: GRA) and E. I. du Pont de Nemours & Co. (NYSE: DD) today announced the cross-licensing of key genetic engineering rights covering gene delivery. Gene delivery refers to the process of inserting genes into living cells to give those cells new traits. Under the agreement, Grace and Agracetus, Inc., its wholly owned subsidiary, jointly became the exclusive commercial licensee for all mammalian applications of Du Pont's Biolistic(R) gene delivery technology, and received a paid-up non-exclusive license for plant applications. These licenses provide Agracetus freedom to operate as it develops transgenic products for itself and its customers.
 Du Pont received a license to Agracetus technology which covered aspects of the Biolistic(R) Particle Delivery System (PDS) and will continue to be the sole provider of commercial licenses for all plant applications of Biolistic(R) technology. Terms of the agreement were not disclosed.
 Gene delivery is considered to be one of the key life science technologies of the 1990s due to its projected major impact in both health care and agribusiness. Applications encompass such leading edge developments as human gene therapy, genetic vaccines, and transgenic plants and animals.
 Biolistics is a specific gene delivery method wherein DNA-coated particles are mechanically accelerated into cells. Once particles are inside the cells, the DNA migrates from the particle to become a part of the chromosome of that cell, where it functions like normally resident genes. Through this technique, pre-existing cellular dysfunction can be corrected or new functions enabled. Other methods of gene transfer are also under development, but suffer from various limitations.
 "In our Agracetus subsidiary, we independently developed ACCELL(TM) Gene Delivery, a system which uses the same basic insertion concept but a unique electric discharge propulsion," stated Dr. F. Peter Boer, Grace executive vice president and chief technical officer. "Due to ACCELL's(TM) unique advantages for delivering genes into human tissue, gene therapy has become a major focus of our strategy. We are actively exploring its therapeutic potential for such illnesses as AIDS, Parkinson's disease, cancer, and cardiovascular disease."
 "By consolidating the Biolistic(R) rights with our pre-existing ACCELL(TM) position, Agracetus is now the sole commercial source of particle-mediated gene delivery for biomedical applications, and is the premier provider in plants. We can now aggressively pursue our strategic objectives unimpeded and expand the range and scope of our strategic alliances and product development services," according to Russell Smestad, Agracetus vice president, finance and commercial development.
 Under this agreement, Du Pont will continue to make non-exclusive commercial licenses available for all plant and non-mammalian products as well as use the Biolistic(R) technology internally for strategically important plant applications such as improving yields and quality of major crops. "Importantly, this agreement enables Du Pont and Agracetus, both leaders in plant biotechnology, to execute their respective business plans. In addition, Bio-Rad Laboratories, Du Pont's exclusive marketing agent for Biolistic(R) instruments, will continue to be the sole provider of instruments and research licenses to the scientific and commercial communities," stated Robert T. Giaquinta, manager, biotechnology business development for Du Pont Ag Products.
 Agracetus, Inc. is a leader in gene delivery technology, focused on developing products for the biomedical and agribusiness industries.
 Grace is the world's largest specialty chemicals company with a leadership position in health care.
 Du Pont is a diversified chemical, energy and specialty products company. Du Pont Ag Products is a world leader both in crop protection products and in developing new businesses through plant biotechnology.
 -0- 4/21/92
 /CONTACT: Chuck Suits of W. R. Grace & Co., 800-GRACE99 or 407-362-2600; or Suzanne C. Shaw of Du Pont External Affairs, 302-992-6286/
 (GRA DD) CO: W. R. Grace & Co.; E. I. du Pont de Nemours & Co. ST: Florida IN: MTC SU: LIC


SS-JJ -- FL005 -- 0409 04/21/92 09:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1992
Words:648
Previous Article:AMERICAN RELIANCE GROUP REPORTS RECORD FIRST QUARTER RESULTS
Next Article:NEWELL REPORTS RECORD FIRST QUARTER RESULTS


Related Articles
DU PONT TO HOLD FIRST SAE NEWS CONFERENCE MONDAY, FEB. 24
DU PONT COLOR MARKETING MANAGER TO DISCUSS CAR COLOR TRENDS
DU PONT INTRODUCES FIRST RECYCLABLE THERMOPLASTIC COMPOSITE SHEET SYSTEM
GRACE'S CRYOVAC UNIT COMPLETES PURCHASE OF DU PONT CANADA'S FOODSERVICE PACKAGING BUSINESS
DU PONT HONORS 100 EMPLOYEES FOR MARKETING ACHIEVEMENTS
DU PONT HONORS SCIENTISTS AND ENGINEERS
DU PONT HONORS SCIENTISTS AND ENGINEERS
MERCK TO LICENSE TRADEMARK AND MARKETING RIGHTS FOR TWO BRANDS TO THE DU PONT MERCK PHARMACEUTICAL COMPANY AND ITS EUROPEAN SUBSIDIARIES
DU PONT SELLS PLASTIC BOTTLE RECYCLING BUSINESS TO ITW
THE DU PONT MERCK PHARMACEUTICAL COMPANY AND BRITISH TECHNOLOGY GROUP USA SIGN AGREEMENT TO TRANSFER PHARMACEUTICAL TECHNOLOGIES

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters